idarubicin has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coombs, CC; Mathews, SP | 1 |
| Dragojew, S; Ilnicki, K; Jóźwiak, Z; Marczak, A; Maszewski, J | 1 |
2 other study(ies) available for idarubicin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Bone Marrow; Diabetes Mellitus, Type 2; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Multiple Primary; Remission Induction; Tretinoin | 2018 |
The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts.
Topics: Apoptosis; Calcium; Caspase 3; Cell Line; Daunorubicin; Diabetes Mellitus, Type 2; Enzyme Activation; Fibroblasts; Humans; Idarubicin; Inhibitory Concentration 50; Intracellular Space; Membrane Potential, Mitochondrial; Trisomy | 2008 |